Erik Greb

Erik Greb joined the staff of Neurology Reviews in January 2012. Since then, he has attended scientific conferences, conducted video interviews, and written about clinical research in multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, stroke, and other neurologic disorders. In addition to news articles, Erik has written investigative stories about multiple sclerosis, headache, and epilepsy. He previously wrote about pharmaceutical manufacturing, drug formulation and delivery, quality assurance, and regulation for Pharmaceutical Technology.

News

Long-term benefit for DBS in treating Parkinson’s disease motor symptoms

Author:: Erik Greb

Publish date: April 26, 2021

“Both STN and GPi DBS maintained motor benefit out to 10 years, with improvements seen in tremor and rigidity, greater than bradykinesia.”

News

Intranasal third-generation CGRP effective for acute migraine

Author:: Erik Greb

Publish date: April 23, 2021

Among patients taking zavegepant, more than 20% achieved pain freedom and 40% were relieved of their most bothersome symptom.

News

COVID-19–related inflammatory syndrome tied to neurologic symptoms in children

Author:: Erik Greb

Publish date: April 16, 2021

Neurologic symptoms appear to be more common in severe presentations of this syndrome.

News

Radially adjustable ‘Tigertriever’ safe, effective in stroke

Author:: Erik Greb

Publish date: March 31, 2021

The novel device may increase the options for endovascular therapy.

News

Neurologic drug prices jump 50% in five years

Author:: Erik Greb

Publish date: March 16, 2021

Most of the increased cost was due to rising costs for neuroimmunology drugs, mainly for those used to treat multiple sclerosis (MS).

News

EEG data may help aid diagnosis, treatment of focal epilepsy

Author:: Erik Greb

Publish date: February 25, 2021

“A patient with epilepsy may have a unique combination of seizure rhythms that can inform the days and timing of his or her highest seizure risk.”<...

News

Prostate drugs tied to lower risk for Parkinson’s disease

Author:: Erik Greb

Publish date: February 11, 2021

If confirmed by additional trials, glycolysis-enhancing drugs could be a new option to slow progression of Parkinson’s disease,

News

Researchers examine factors associated with opioid use among migraineurs

Author:: Erik Greb

Publish date: February 11, 2021

Despite ample evidence of opioids’ harmful effects when administered for migraine, about one-third of migraineurs report taking them.

News

Blood biomarker may predict Alzheimer’s disease progression

Author:: Erik Greb

Publish date: January 22, 2021

P-tau181 and NfL in blood have individual and complementary potential roles in the diagnosis and the monitoring of neurodegenerative disease.

News

High blood pressure at any age speeds cognitive decline

Author:: Erik Greb

Publish date: December 17, 2020

Prehypertension was also linked to accelerated cognitive decline.

News

Blood pressure treatment reduces bleeding in ICH

Author:: Erik Greb

Publish date: November 24, 2020

The management of blood pressure in ICH is complex. Timing, type of drug, and type of patient must be considered.

News

Concussion linked to risk for dementia, Parkinson’s disease, and ADHD

Author:: Erik Greb

Publish date: November 24, 2020

A history of multiple concussions strengthened the association between concussion and subsequent mood and anxiety disorder, dementia, and Parkinson...

News

Late-onset epilepsy tied to a threefold increased dementia risk

Author:: Erik Greb

Publish date: November 12, 2020

The findings support a bidirectional relationship between dementia and epilepsy.

News

Gene-replacement therapy shows promise in X-linked myotubular myopathy

Author:: Erik Greb

Publish date: November 5, 2020

An investigational gene therapy decreases ventilator dependence and may improve motor development in children with a rare, life-threatening disease...

News

Ataluren delays disease milestones in patients with nonsense mutation DMD

Author:: Erik Greb

Publish date: October 27, 2020

Patients who received ataluren in addition to standard of care were 2.2 years older when they lost ambulation, compared with patients receiving sta...